Clinical Trial Update: Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating adalimumab in peripheral spondyloarthritis has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Spondyloarthritis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Peripheral Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-11-25